European Journal of Clinical Microbiology and Infectious Diseases

, Volume 12, Issue 10, pp 778–782

Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy

  • W. Lo
  • E. Whimbey
  • L. Elting
  • R. Couch
  • F. Cabanillas
  • G. Bodey
Notes

DOI: 10.1007/BF02098469

Cite this article as:
Lo, W., Whimbey, E., Elting, L. et al. Eur. J. Clin. Microbiol. Infect. Dis. (1993) 12: 778. doi:10.1007/BF02098469

Abstract

A study was conducted to determine if a two-dose regimen of influenza vaccine would enhance the immunologic response of 41 patients with lymphoma receiving chemotherapy. Hemagglutinin-inhibiting antibody responses to influenza A/H1N1, A/H3N2 and B virus occurred in 32 %, 24 % and 20 % of patients following one dose, and in 49 %, 41 % and 46 % of patients following two doses, respectively. Responses to one or more vaccine components occurred in 42 % of patients after one dose and in 71 % after two doses. Fifty percent of the patients who did not respond after one dose responded after two doses. A two-dose regimen of influenza immunization may significantly enhance the response rate of cancer patients receiving chemotherapy.

Copyright information

© Friedr. Vieweg & Sohn Verlagsesellschaft mbH 1993

Authors and Affiliations

  • W. Lo
    • 1
  • E. Whimbey
    • 1
  • L. Elting
    • 1
  • R. Couch
    • 3
  • F. Cabanillas
    • 2
  • G. Bodey
    • 1
  1. 1.Department of Medical Specialities, Section of Infectious DiseasesThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Hematology, Section of LymphomaThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Influenza Research CenterBaylor College of MedicineHoustonUSA